Department of Pediatrics, The Second Hospital of Anhui Medical University, Hefei, China.
Department of Pediatrics, The Fourth Hospital of Anhui Medical University, Hefei, China.
Leuk Lymphoma. 2020 Dec;61(12):2850-2858. doi: 10.1080/10428194.2020.1786557. Epub 2020 Jul 9.
This study evaluated the long-term therapeutic effect and prognostic factors of acute lymphoblastic leukemia (ALL) in 100 young Chinese children (<2 years old) who were enrolled in the Shanghai Children's Medical Center (SCMC)-ALL-2009 study in five pediatric hematological disease centers based on collaboration. The 5-year and 10-year event-free survivals (EFS) were 74.7 ± 3.2% and 73.3 ± 3.4%. The 10-year EFS rates for low risk, intermediate-risk, and high-risk patients were 81.9 ± 5.0%, 71.3 ± 4.3%, and 22.2 ± 13.9%, respectively. Relapse occurred in 19 patients. MRD results on day 55, good or poor response to prednisolone, and age at diagnosis were shown to have important prognostic and therapeutic implications. Compared with the SCMC-ALL-2005 protocol, showed that the 10-year-EFS and 10-year-overall survival of the SCMC-ALL-2009 protocol were better than that of the -2005 protocol. Notably, the intermediate-risk group was improved after the chemotherapy intensity was strengthened.
本研究评估了 100 例中国年轻儿童（<2 岁）急性淋巴细胞白血病（ALL）的长期治疗效果和预后因素，这些儿童均基于协作在五个儿科血液病中心参加了上海儿童医学中心（SCMC）-ALL-2009 研究。5 年和 10 年无事件生存率（EFS）分别为 74.7±3.2%和 73.3±3.4%。低危、中危和高危患者的 10 年 EFS 率分别为 81.9±5.0%、71.3±4.3%和 22.2±13.9%。19 例患者发生复发。第 55 天的 MRD 结果、对泼尼松的良好或不良反应以及诊断时的年龄均显示出重要的预后和治疗意义。与 SCMC-ALL-2005 方案相比，SCMC-ALL-2009 方案的 10 年 EFS 和 10 年总生存率优于 SCMC-ALL-2005 方案。值得注意的是，在强化化疗强度后，中危组得到了改善。
